-
Featured Authors
-
Archives
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Tracy Cooley
Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.
Latest Posts
Partnership for Part D Access Launches Today
BIO joins patient groups and other health care stakeholders today to announce the formation of the Partnership for Part D Access, a coalition committed to protecting access to necessary medications for patients in the Medicare Part D prescription drug program. The Partnership for Part D Access opposes a proposed rule from the U.S. Centers for Medicare & Medicaid Services (CMS) that would reduce the number of “protected classes” of medication in Medicare Part D, specifically Read More >
Bioterrorism: Assessing the Threat
Recently, the House of Representatives Homeland Security Committee Subcommittee on Emergency Preparedness, Response, and Communications held a hearing on bioterrorism and biological warfare.Tom Inglesby, MD, University of Pittsburgh Medical Center, Center for Health Security and Robert P. Kadlec, MD, Center for a New American Security, presented testimony outlining their concerns on current threats to public safety and recommendations for emergency preparedness. Drs. Inglesby and Kadlec asserted that the risk of biological attacks on the U.S. Read More >
National Health Interview Survey: Adult Vaccination Rates Need Boost
The Centers for Disease Control and Prevention (CDC) recently released immunization coverage estimates from the 2012 National Health Interview Survey (NHIS) for six vaccines routinely recommended for adults including pneumococcal, tetanus and Tdap, Hepatitis A, Hepatitis B, herpes zoster (shingles), and Human papillomavirus (HPV). These data indicate little overall improvement in vaccination coverage among adults from 2011 to 2012. Compared with 2011, modest increases occurred in three vaccines: Tdap, herpes zoster and HPV. However, vaccination Read More >
Doping Undermines the Mission of Biotechnology
The Olympic Games in Sochi captures the world’s attention as athletes compete to bring home gold. Our industry plays a key role in helping to maintain the integrity and honor of sports and competition by remaining vigilant in our anti-doping efforts. Doping undermines the integrity of our industry’s core mission of serving patients through drug discovery and development. The same medicines that can be used to help children with devastating genetic deficiencies and growth disorders, Read More >
FDA Week: For Biologics, A Name Isn’t Just A Name (Jim Greenwood op-ed)
What is in a name? Names help make medicinal products more easily distinguishable by doctors, pharmacists and patients. When you are talking about biologics, complex medicines that are manufactured using living organisms, and biosimilars, medicines that are similar to, but not the same as, innovator biologics, naming is a significant consideration. As a pathway for biosimilars approval is implemented, a clear priority should be to craft a naming convention that both contributes to patient safety Read More >
